NYKD Share Price Performance
NOK 3.16
1.34 (73.72%)
29.8% undervalued intrinsic discount
NOK 4.50
Fair Value
Price NOK 3.16
AnalystConsensusTarget NOK 4.50
Fair ValueNOK 4.50
Share Pricen/a
New Narrative • May 19
Nykode Therapeutics AS Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
NYKD Community Narratives
AN
Fair Value
·Fair Value NOK 4.5 29.8% undervalued intrinsic discount
Head And Neck Cancer Trial Progress And Cash Runway Will Support Long Term Potential
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Head And Neck Cancer Trial Progress And Cash Runway Will Support Long Term Potential
Nykode Therapeutics is pushing its lead head and neck cancer treatment into a larger study, a step that could clarify whether earlier encouraging results hold up in real-world use. The upside comes with a key catch: the company burns cash and needs its trials, partners, and a pending tax decision to line up before funding pressure returns.Read more
AN
NOK 4.5
29.8% undervalued intrinsic discount
Fair Value
Profit Margin
15.16%
Future PE
36.22x
Price in 2029
NOK 5.47
Trending Discussion
Recently Updated Narratives
AN
Head And Neck Cancer Trial Progress And Cash Runway Will Support Long Term Potential
Fair Value: NOK 4.5 29.8% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Nykode Therapeutics AS Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 26, 2026
- -0.046
- 100.00%
- -2,681.47%
- 0%
About NYKD
- Founded
- 2006
- Employees
- 57
- CEO
- WebsiteView website
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include ABI-SUVA for targeting HPV16+ induced malignancies, with head, and neck cancer as the primary indication is in Phase 2 randomized controlled trial. It also offers VB10.NEO, which is in Phase1b VB-N-02 trial; technology platform, which combines genes with desired properties to make novel compounds by creating a new code. Nykode Therapeutics AS was founded in 2006 and is headquartered in Oslo, Norway.
